Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

The response of thrombosis in the portal vein or hepatic vein in hepatocellular carcinoma to radiation therapy

  • Bae, Bong Kyung (Department of Radiation Oncology, Kyungpook National University School of Medicine) ;
  • Kim, Jae-Chul (Department of Radiation Oncology, Kyungpook National University School of Medicine)
  • Received : 2016.02.06
  • Accepted : 2016.06.21
  • Published : 2016.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The purpose of current study is to evaluate the response of the patients with portal vein thrombosis (PVT) or hepatic vein thrombosis (HVT) in hepatocellular carcinoma (HCC) treated with three-dimensional conformal radiation therapy (3D-CRT). In addition, survival of patients and potential prognostic factors of the survival was evaluated. Materials and Methods: Forty-seven patients with PVT or HVT in HCC, referred to our department for radiotherapy, were retrospectively reviewed. For 3D-CRT plans, a gross tumor volume (GTV) was defined as a hypodense filling defect area in the portal vein (PV) or hepatic vein (HV). Survival of patients, and response to radiation therapy (RT) were analyzed. Potential prognostic factors for survival and response to RT were evaluated. Results: The median survival time of 47 patients was 8 months, with 1-year survival rate of 15% and response rate of 40%. Changes in Child-Pugh score, response to RT, Eastern cooperative oncology group performance status (ECOG PS), hepatitis C antibody (HCVAb) positivity, and additional post RT treatment were statistically significant prognostic factors for survival in univariate analysis (p = 0.000, p = 0.018, p = 0.000, p = 0.013, and p = 0.047, respectively). Of these factors, changes in Child-Pugh score, and response to RT were significant for patients' prognosis in multivariate analysis (p = 0.001 and p = 0.035, respectively). Conclusion: RT could constitute a reasonable treatment option for patients with PVT or HVT in HCC with acceptable toxicity. Changes in Child-Pugh score, and response to RT were statistically significant factors of survival of patients.

Keywords

References

  1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76. https://doi.org/10.1053/j.gastro.2007.04.061
  2. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States: prognostic features, treatment outcome, and survival. Cancer 1996;77:2217-22. https://doi.org/10.1002/(SICI)1097-0142(19960601)77:11<2217::AID-CNCR6>3.0.CO;2-M
  3. Pirisi M, Avellini C, Fabris C, et al. Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study. J Cancer Res Clin Oncol 1998;124:397-400. https://doi.org/10.1007/s004320050189
  4. Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999;229:790-9. https://doi.org/10.1097/00000658-199906000-00005
  5. Kim DY, Park W, Lim DH, et al. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer 2005;103:2419-26. https://doi.org/10.1002/cncr.21043
  6. Minagawa M, Makuuchi M, Takayama T, Ohtomo K. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg 2001;233:379-84. https://doi.org/10.1097/00000658-200103000-00012
  7. Ando E, Tanaka M, Yamashita F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002;95:588-95. https://doi.org/10.1002/cncr.10694
  8. Kondo K, Chijiiwa K, Kai M, et al. Surgical strategy for hepatocellular carcinoma patients with portal vein tumor thrombus based on prognostic factors. J Gastrointest Surg 2009;13:1078-83. https://doi.org/10.1007/s11605-009-0854-2
  9. Lee DS, Seong J. Radiotherapeutic options for hepatocellular carcinoma with portal vein tumor thrombosis. Liver Cancer 2014;3:18-30. https://doi.org/10.1159/000343855
  10. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:62-7. https://doi.org/10.1002/hep.510290145
  11. Kim TH, Kim DY, Park JW, et al. Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am J Clin Oncol 2006;29:568-75. https://doi.org/10.1097/01.coc.0000239147.60196.11
  12. Zeng ZC, Fan J, Tang ZY, et al. Prognostic factors for patients with hepatocellular carcinoma with macroscopic portal vein or inferior vena cava tumor thrombi receiving external-beam radiation therapy. Cancer Sci 2008;99:2510-7. https://doi.org/10.1111/j.1349-7006.2008.00981.x
  13. Huang YJ, Hsu HC, Wang CY, et al. The treatment responses in cases of radiation therapy to portal vein thrombosis in advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2009;73:1155-63. https://doi.org/10.1016/j.ijrobp.2008.06.1486
  14. Kim SH, Kang MK, Yea JW, Kim SK, Choi JH, Oh SA. The impact of beam angle configuration of intensity-modulated radiotherapy in the hepatocellular carcinoma. Radiat Oncol J 2012;30:146-51. https://doi.org/10.3857/roj.2012.30.3.146
  15. Zhang XB, Wang JH, Yan ZP, Qian S, Du SS, Zeng ZC. Hepatocellular carcinoma with main portal vein tumor thrombus: treatment with 3-dimensional conformal radiotherapy after portal vein stenting and transarterial chemoembolization. Cancer 2009;115:1245-52. https://doi.org/10.1002/cncr.24139
  16. Rim CH, Yang DS, Park YJ, Yoon WS, Lee JA, Kim CY. Effectiveness of high-dose three-dimensional conformal radiotherapy in hepatocellular carcinoma with portal vein thrombosis. Jpn J Clin Oncol 2012;42:721-9. https://doi.org/10.1093/jjco/hys082
  17. Yoon SM, Lim YS, Won HJ, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys 2012;82:2004-11. https://doi.org/10.1016/j.ijrobp.2011.03.019
  18. Lee JH, Kim DH, Ki YK, et al. Three-dimensional conformal radiotherapy for portal vein tumor thrombosis alone in advanced hepatocellular carcinoma. Radiat Oncol J 2014;32:170-8. https://doi.org/10.3857/roj.2014.32.3.170
  19. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2. https://doi.org/10.1002/hep.24199
  20. Cheng JC, Wu JK, Huang CM, et al. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. Int J Radiat Oncol Biol Phys 2002;54:156-62.
  21. Cheng JC, Wu JK, Huang CM, et al. Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description. Radiother Oncol 2002;63:41-5. https://doi.org/10.1016/S0167-8140(02)00061-0
  22. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002;53:810-21. https://doi.org/10.1016/S0360-3016(02)02846-8
  23. Liang SX, Zhu XD, Xu ZY, et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys 2006;65:426-34. https://doi.org/10.1016/j.ijrobp.2005.12.031
  24. Son SH, Jang HS, Jo IY, et al. Significance of an increase in the Child-Pugh score after radiotherapy in patients with unresectable hepatocellular carcinoma. Radiat Oncol 2014;9:101. https://doi.org/10.1186/1748-717X-9-101
  25. Tazawa J, Maeda M, Sakai Y, et al. Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. J Gastroenterol Hepatol 2001;16:660-5. https://doi.org/10.1046/j.1440-1746.2001.02496.x
  26. Yamada K, Izaki K, Sugimoto K, et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003;57:113-9. https://doi.org/10.1016/S0360-3016(03)00434-6
  27. Toya R, Murakami R, Baba Y, et al. Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma. Radiother Oncol 2007;84:266-71. https://doi.org/10.1016/j.radonc.2007.07.005
  28. Ishikura S, Ogino T, Furuse J, et al. Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Clin Oncol 2002;25:189-93. https://doi.org/10.1097/00000421-200204000-00019
  29. Lin CS, Jen YM, Chiu SY, et al. Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy. Jpn J Clin Oncol 2006;36:212-7. https://doi.org/10.1093/jjco/hyl006
  30. Guha C, Kavanagh BD. Hepatic radiation toxicity: avoidance and amelioration. Semin Radiat Oncol 2011;21:256-63. https://doi.org/10.1016/j.semradonc.2011.05.003
  31. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-22.
  32. Pan CC, Kavanagh BD, Dawson LA, et al. Radiationassociated liver injury. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S94-100. https://doi.org/10.1016/j.ijrobp.2009.06.092

Cited by

  1. New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus vol.5, pp.2, 2016, https://doi.org/10.14218/jcth.2016.00071
  2. Intensity-modulated radiotherapy for hepatocellular carcinoma: dosimetric and clinical results vol.8, pp.35, 2017, https://doi.org/10.18632/oncotarget.19219
  3. The Clinical Utilization of Radiation Therapy in Korea between 2011 and 2015 vol.50, pp.2, 2016, https://doi.org/10.4143/crt.2017.096
  4. Nomogram for Predicting the Prognosis of Patients with Hepatocellular Carcinoma Presenting with Pulmonary Metastasis vol.13, pp.None, 2016, https://doi.org/10.2147/cmar.s296020
  5. Predictive factors for survival following stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumour thrombosis and construction of a nomogram vol.21, pp.1, 2016, https://doi.org/10.1186/s12885-021-08469-1